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Abstract The aim of the study was to assess the safety and
effectiveness of stereotactic brain tumour biopsy (STx biopsy)
guided by low-field intraoperative magnetic resonance imaging
(iMRI) in comparison with its frameless classic analogue based
on a prospective randomized trial. A pilot group of 42 brain
tumour patients was prospectively randomized into a low-field
iMRI group and a control group that underwent a frameless
STx biopsy. The primary endpoints of the analysis were post-
operative complication rate and diagnostic yield, and the sec-
ondary endpoints were length of hospital stay and duration of
operation. The iMRI group (21 patients) and the control group
(21 patients) did not differ significantly according to demo-
graphic and epidemiological data. No major postoperative
complications were noted in either group. In addition, no sig-
nificant differences in the diagnostic yield (p=1.00) and length
of hospital stay (p=0.16) were observed. The mean total OR
time was 111±24 min in iMRI and 78±29 min in the control
group (p=0.0001). Usage of iMRI may prolong the time of the
procedure but seems to be comparable in safety and effective-
ness to the standard frameless STx biopsy.
Keywords Intraoperative magnetic resonance . Stereotactic
biopsy . Brain tumour . Frameless stereotaxy . Image-guided
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Introduction
Stereotactic brain biopsy (STx biopsy) offers a relatively
straightforward, accurate and safe method of obtaining diagnos-
tic tissue [20]. Frameless computer-based neuronavigation is
now widely used in brain tumour surgery. It has many advan-
tages over frame-based techniques—it is less time-consuming,
involves much less human resources, it is better tolerated by the
patient, more cost-effective and provides similar accuracy to the
rigid frame [8, 13]. One of the methods applied to improve
diagnostic yield and safety is the usage of intraoperative mag-
netic resonance imaging (iMRI), proposed by Bernays et al. in
2002 [4].
The iMRI guidance provides near real-time imaging during a
neurosurgical procedure. It provides an image of the actual
intraoperative situation, which can be useful when taking into
account brain-shift. This phenomenon, almost always observed
during extensive cranial procedures, can occur even during
minor procedures such as STx biopsy [24, 25]. Besides the
obvious indications for the use of iMRI guidance provided in
previous papers, including STx biopsy of very small, deeply
localized or cystic lesions [4, 19, 23], it is particularly useful in
two other circumstances. The first is when a high resolution
three-dimensional (3D) volume modality was not obtained dur-
ing preoperative diagnostic imaging. High resolution 3DMR or
CT images are used as reference examinations allowing the
preoperative so called registration of the patient’s head in the
neuronavigation system. Points collected from the patient’s head
are subsequently merged with the surface of the patient’s head
3D model developed basing on the previously mentioned 3D
modalities. When using low-field iMRI, there is no need for
head registration, which makes it unnecessary to perform addi-
tional preoperative imaging given the associated accumulative
increase in cost and risks [3, 19, 22, 26, 27]. In our study, the
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total number of patients with insufficient neuroimaging—who
were scheduled for the STx biopsy basing on a conventional
MR study, which did not contain this particular sequence—is
over 30 %.
Moreover, frameless iMRI-guided STx biopsy is relatively
uncomplicated and technically straightforward and can be in-
troduced as the first procedure during training in neurosurgical
intraoperative imaging.
Although the usefulness of ultra-low-field iMRI in STx
biopsy was subsequently confirmed by other authors, according
to our knowledge, no previous published studies have compared
iMRI to preoperative MRI for a brain tumour biopsy according
to evidence-based medicine (EBM) guidelines [7, 19, 23].
Though this method has been subject to slight criticism, it has
consequently been applied in neurosurgical daily practise in
recent years [1, 25, 29].
The aim of our study was to verify the safety and effec-
tiveness of the STx biopsy guided by low-field iMRI in
comparison with its frameless classic analogue basing on a
prospective randomized parallel-group, controlled trial. In the




Between June 2009 and August 2012, patients whowere—follo
wing contemporary recommendations [28]— scheduled to un-
dergo STx biopsy were prospectively recruited for the study.
Themajority of the patients suffered from superficially localized
tumours and was scheduled for an open surgery unless a radi-
ologist suspected lymphoma or the general medical condition of
the patient was unsatisfactory. An exception from this rule was
made for pathologies localized in the eloquent brain area. In
general, in such cases, we performed STx biopsy prior to the
surgical excision to adjust the extent and technique of the desired
subsequent resection basing on the obtained histopathology. An
approval of the local ethics committee was obtained, and each
patient signed a written consent to participate in the study.
Graphical illustration of the recruitment and allocation process
is presented in Fig. 1.
Inclusion criteria
The inclusion criteria were as follows: male and female pa-
tients ≥18 years with supratentorial brain tumour scheduled to
undergo STx biopsy. The estimated number of patients needed
to reveal the difference of over 5 % between primary
endpoints’—diagnostic yield and complications ratio—at the
level of significance 0.05 and power 80 % was 465 per each
arm [32, 34].
Exclusion criteria
Patients unable to provide informed consent and those with
metal implants which could disrupt or influence the headMR
study were excluded from the study.
Allocation
Patients were prospectively allocated into the iMRI and the
control group by minimization according to demographic
(gender and age) and epidemiologic data (preoperative East-
ern Cooperative Oncology Group (ECOG) performance
status—a scale providing information about neurological
and social status of a patient with oncological disease, max-
imum tumour diameter, presence of contrast enhancement,
independent risk factors of haemorrhage—basal and thalam-
ic localization and preoperative diabetes) [10, 15, 17, 18].
Intervention
After being transferred to the operating room, each patient was
sedated with an intravenous infusion of remifentanil with
passive oxygen therapy and monitoring of vital functions.
Additionally, the sites of head holder pins and skin incision
Fig. 1 Graphical illustration of the recruitment and randomization
process. DGN diagnosed, STx biopsy stereotactic biopsy
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were anaesthetized with 1 % lignocaine. All biopsies in both
groups were performed via a 6-mm-burr hole with the use of
the Vertec system (Medtronic Navigation, Louisville, CO,
USA). A ferromagnetic passively navigated 2.2-mm sidecut
with a 9-mm-cutting window length biopsy needle was used
(Fig. 2). Thus, each sample had an estimated volume of over
30 mm3. All operations were performed by one of the three
first authors.
In the iMRI-guided group, the head of each patient was
immobilized with a three-pin iMRI-compatible headholder.
The PoleStar N20 iMRI system (Medtronic Navigation, Lou-
isville, CO, USA) with a 0.15Tconstant magnet was used in all
procedures. Subsequently, after the patient’s positioning, the
preoperative reference examination was routinely carried out
(T1+gadolinum, T2 or FLAIR-weighted—depending on the
pathology and axial 4 mm scans). Images were automatically
transferred into the neuronavigation system (StealthStation,
Medtronic Navigation, Louisville, CO, USA). The entry point,
target and optimal biopsy trajectory were then defined by the
operator on the basis of the obtained iMRI images. Serial tissue
samples (four from the central and another four from the
marginal part of the tumour) were collected according to the
modified protocol described by Shooman et al., which made
the use of an intraoperative histopathological examination ob-
solete [28]. Following each operation, a control iMRI (T1-
weighted, axial and 4-mm scan examination) was routinely
performed to confirm and document the proper targeting and
to exclude postoperative hyperacute intraparenchymal bleeding
as proposed by Bernays et al. [4, 7] (Fig. 3).
A frameless STx biopsy was performed for each patient
from the control group with the use of a neuronavigation
system. The entry point, target and optimal biopsy trajectory
were defined by the operator before the procedure on the basis
of the preoperatively obtained high-field MR images with the
use of a neuronavigation workstation (Cranial 5; StealthStation
Application Software, Medtronic Navigation, Louisville, CO,
USA). A schematic presentation of the intervention in both the
study and control groups is presented in Fig. 4.
Following surgery, the specimens were sent for independent
histopathological analysis. An open resectionwas subsequently
performed in four patients in the iMRI group and five in the
non-iMRI group.
Postoperative care
Postoperative care was conducted according to standard
protocols and clinical guidelines. A postoperative follow-
up head CT was subsequently performed 4 to 6 h after each
procedure. All patients were followed up with a clinical
examination 2 weeks postoperatively performed by an
blinded for the allocation investigator.
Data collection
Demographic and epidemiological data were collected pro-
spectively. The primary endpoints were the ratio of acute
postoperative complications and the diagnostic yield. The
presence of acute postoperative complications was noted if
any of the following findings were present: wound site infec-
tion up to 2 weeks after the operation, a new neurological
deficit developed up to 24 h following the operation and
present in a follow up clinical examination 2 weeks postoper-
atively and intraparenchymal hematoma with radiological or
clinical signs of the intracranial expansion. The diagnostic
yield was expressed according to literature as a percentage
of patients in whom the histopathological diagnosis was pos-
sible on the basis of the biological material obtained during the
operation [28]. Secondary endpoints included the preoperative
(LOSpre), postoperative (LOSpost) and total length of hospital
stay (LOS) as well as the preparation (Tprep), operation (Top)
and total operating room (TOR) time. The LOS and T were
routinely measured and recorded in the central hospital files
by independent staff.
Statistical analysis
The study and control group were compared statistically using
STATISTICAv. 9.1 (StatSoft, Inc.) software. Binomial dichot-
omized data (gender, tumour enhancement ratio, independent
bleeding risk factors and diagnostic yield) were compared with
Fig. 2 A ferromagnetic passively navigated sidecut 2.2-mm biopsy
needle. The solid triangle indicates a stopper, allowing to mark the
depth of the needle insertion calculated by the neuronavigation system.
Open triangles indicate passive neuronavigation markers. A close-up
view of a 9-mm long cutting window of the biopsy needle allowing to
obtain a tissue sample of the estimated volume of over 30 mm3 is visible
in the lower-left corner
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the two-tailed Fisher’s exact test. After testing for normal
distribution using the Shapiro–Wilk W test, the Student’s t test
was applied to compare patients’ age, maximum tumour diam-
eter and time of preparation and operation as well as total OR
time. Differences between skewed data were compared: preop-
erative ECOG score and LOS with the Mann–Whitney U test.
A p value of ≤0.05 was considered statistically significant.
This study is registered with clinical trials. Gov. number
NCT 01779219.
Study termination criteria
The interim analysis was performed each year of the study
for safety reasons. We intended to terminate the study if a
complication rate exceeded 6 % (exceeding an average mor-
bidity value reported in literature of 5.5 by 10 %) or if the
revealed diagnostic yield would be lower than 88% (5% less
than the average 93 % value of the diagnostic yield reported
in literature) in either group [4, 13, 17, 20, 28, 30]. Similarly
to previous interim analyses, we did not reveal such viola-
tions of the contemporary standards; therefore, the study was
continued. A considered positive reason for the premature
termination of the study would be the lack of significant
differences in terms of primary endpoints revealed during
the interim analysis of groups exceeding 100 cases each.
Results
The inclusion criteria were met by 42 patients, who were
enrolled in the study as a pilot group. Both the iMRI and
control group consisted of 21 patients. The iMRI and the
control group did not differ significantly in relation to: gender
(p=0.75), age (p=0.45), preoperative ECOG performance
status (p=0.86), maximum tumour diameter (p=0.42), en-
hancement ratio (p=0.50) and independent risk factors for
haemorrhage—basal (p=1.00) and thalamic (p=0.66) locali-
zation of the pathology and preoperative diabetes (p=1.00).
Essential demographic and epidemiologic data are presented
in Tables 1 and 2.
The obtained biopsies were suitable for neuropathological
studies in 20 (95 %) cases from both the iMRI and control
Fig. 3 Example postoperative
iMRI T1-weighted axial 4-mm
control scans. a The left
temporal lobe contrast-
enhancing tumour. b The left
frontal lobe non-enhancing
pathology. The ferromagnetic
biopsy needle has been removed
prior to scanning. The biopsy
site is visible as a black spot— a
small air bubble is indicated by
the open triangles
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group (p=1.00). In terms of postoperative complications, one
case of intraparenchymal haemorrhage, treated conservatively,
was noted in the control group (p=1.00). We did not reveal any
cases of hyperacute bleeding in the postoperative iMRI scans.
The total, pre- and postoperative lengths of hospital stay
were not statistically significantly different between both
groups. The mean Tprep and Top differed between both
groups (p=0.004 and p=0.024, respectively). The mean
TOR was 111±24 min (iMRI) and 78±29 min (control) and
also differed significantly (p<0.0001). The summary of de-
pendent variables supplemented by results of the statistical
analysis is presented in Table 3 and Fig. 5.
Discussion
The use of iMRI guidance for STx biopsies allows to over-
come the lack of a preoperative high-field 3D study and to
perform the procedure basing on near real-time imaging. In
the interim analysis of our prospective, randomized and con-
trolled trial, we noted that both types of biopsies—with and
without intraoperative imaging—were comparably effective
and safe with the prolongation of the iMRI-guided procedure
over 30 min as compared to the classically navigated one.
In 2002, Bernays et al. stated that intraoperative imaging with
the use of low-field intraoperative magnetic resonance may
improve diagnostic yield—mainly through the avoidance of the
brain-shift phenomenon influence—with relatively low morbid-
ity and low complication rates [4]. Since then, a number of
authors confirmed these findings based on relatively small cohort
observations [7, 19]. Additionally, as proposed by Schulder and
Spiro, iMRI makes intraoperative histopathology obsolete and
can be routinely used for stereotactic biopsies in a regular neu-
rosurgical practise [23]. However, it should also be taken into
account that the use of iMRI may prolong and technically
complicate the operation [9, 24, 25]. Additionally, the quality
of the intraoperatively obtained 4-mm-thick scans, compared to
the high-field (1.5 or 3 T) 3D volume diagnostic ones, may be
considered insufficient to plan the optimal biopsy trajectory in
relation to all the critical structures such as cortical or peritumoural
vessels. These may—at least theoretically—provide an increased
risk of morbidity or misdiagnosis.
Due to the fact that the main objective of the implementation
of iMRI is usually real intraoperative imaging, one may not
expect that it could also reasonably replace preoperative high
resolution modalities, which is the major case in our study. The
true value of iMRI guidance in STx biopsies has not been
validated scientifically. Until now, there are no papers available
comparing iMRI to preoperative MRI for STx biopsies. There-
fore, there is an unquestionable need to verify the effectiveness
and safety of the use of iMRI to conduct frameless brain tumour
biopsies, preferably using the principles of EBM [12, 21, 33].
Fig. 4 Schematic presentation
of the intervention in both study
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Our study is a prospective randomized trial, which is its
obvious strength. It is open-label, with no blinding of pa-
tients and investigators and with no attempt made at allocation
concealment which could be considered as a pitfall. These
features of the study were necessitated by the specifics of the
intervention [25]. Additionally, the histopathological assessment
Table 1 Characteristics of the patients. Completed with the allocation information, demographic and epidemiological information as well as
pathology description
Allocation Sex Age WHO Maximum Diameter [mm] Enhancement Dominant hemisphere Lobe Pathology
P 01 Non-iMRI Male 36 3 26 – – F + P Limph
P 02 iMRI Female 77 2 52 + – T+P Hgg
P 03 Non-iMRI Female 67 2 45 + + T + P Hgg
P 04 iMRI Female 60 2 55 + – P Hgg
P 05 iMRI Male 46 2 69 + + T Hgg
P 06 iMRI Female 64 1 25 + + P Infl
P 07 Non-iMRI Male 57 1 60 + + T + P Limph
P 08 Non-iMRI Male 56 2 29 – – F –
P 09 Non-iMRI Female 40 2 31 – + F Lgg
P 10 iMRI Female 77 3 69 + – P Hgg
P 11 iMRI Female 48 2 64 + + F Hgg
P 12 Non-iMRI male 47 2 64 + – F Hgg
P 13 Non-iMRI Female 73 2 50 + + P Hgg
P 14 Non-iMRI Female 65 3 77 – + T + P Lgg
P 15 iMRI Male 73 3 39 + – T Limph
P 16 iMRI Male 22 1 36 – + F Lgg
P 17 Non-iMRI Male 61 2 45 + + F Hgg
P 18 Non-iMRI Male 80 3 38 – – T Lgg
P 19 iMRI Male 19 1 8 + – T Limph
P 20 Non-iMRI Male 60 1 50 + + F + T + P Hgg
P 21 Non-iMRI Female 77 3 42 + – T Hgg
P 22 iMRI Male 44 1 60 – + F + T Lgg
P 23 iMRI Female 46 3 24 + – P Limph
P 24 iMRI Male 34 2 64 + + T Lgg
P 25 iMRI Male 50 3 59 + – P + O Limph
P 26 iMRI Male 64 2 60 + – F Hgg
P 27 iMRI Male 63 2 35 – + F + T Lgg
P 28 Non-iMRI Male 51 1 51 + + T Hgg
P 29 Non-iMRI Male 38 0 90 – – F + T + P Lgg
P 30 Non-iMRI Male 52 4 67 + – F Hgg
P 31 iMRI Male 57 3 46 + – F Limph
P 32 Non-iMRI Male 60 2 48 + – T Hgg
P 33 Non-iMRI Female 71 2 52 + – T Hgg
P 34 iMRI Male 50 1 74 – + F + P Lgg
P 35 Non-iMRI Male 49 2 48 + + P + O Hgg
P 36 Non-iMRI Female 32 0 71 – + F Lgg
P 37 iMRI Male 32 1 16 – + F Infl
P 38 iMRI Female 28 1 66 + + T Hgg
P 39 Non-iMRI Female 63 2 80 + – T + O Hgg
P 40 iMRI Male 72 3 62 + + F –
P 41 Non-iMRI Female 29 0 75 – – F + T Lgg
P 42 iMRI Male 60 2 35 + – T Lgg
F frontal lobe, P parietal lobe, T temporal lobe, O occipital lobe, Lgg low grade gliomas, Hgg high grade gliomas, Limph liphoma, Infl inflammation
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was done by an independent specialist who was masked to the
treatment allocation.
An important point of the study is the fact that it was not
possible to compare results of the histopathological exami-
nation of the biopsy specimens with those of the examination
of all of the tumour tissue. This was due to a small number of
patients who underwent subsequent tumour resection. As we
obtained relatively large tissue samples (each sample volume
reaching 30 mm3), we decided to analyse the diagnostic
yield, expressing the number of cases in which it was possi-
ble to obtain reliable results of histopathological examina-
tion. The same methodology was implemented by numerous
previous authors assessing or comparing various techniques
of stereotactic biopsy [4, 8, 13, 28]. Our findings might also
be restricted by the fact that our study was conducted at only
one centre. However, three surgeons performed operations,
which may provide generalizability.
Our results were comparable with those from available
literature in terms of the diagnostic yield: 95 % in both
groups versus a reported average of 93 % (between 92 and
100%) and safety—no observed significant complications in
both groups versus an average of 5.5 % incidence of mor-
bidity reported in literature [4, 13, 17, 20, 28, 30]. We did not
reveal significant difference in terms of the length of hospital
stay between both groups. An insignificant shortening of
total LOS in the iMRI arm may be caused by the lack of
need for preoperative imaging dedicated to neuronavigation
purposes. The number of patients admitted without full
Table 2 Independent variables analysed among iMRI and control group. Mean ± standard deviation, median with (interquartile range) or percentile
values were expressed
Variables iMRI (n=21) Control (n=21) P
Age 52±17 55±15 0.46
Gender [male] 67 % 57 % 0.75
ECOG performance statusa 2 (2) 2 (1) 0.86
Maximum tumour diameter [mm] 48±19 54±18 0.32
Tumour enhancement ratio 76 % 62 % 0.50
Bleeding risk factorsb
Basal localization 38 % 43 % 1.00
Thalamic localization 10 % 19 % 0.66
Diabetes 27 % 27 % 1.00
a Eastern Cooperative Oncology Group performance status—a scale which provides information about neurological and social status and indepen-
dency of patient with oncological disease
b According to McGirt et al. [17]
Table 3 The summary of dependent variables supplemented by results of the statistical analysis. Mean ± standard deviation, median with
(interquartile range) or percentile values were expressed
Variables iMRI (n=21) Control (n=21) P
Time [min]
Tprep 53±22 34±20 0.004
Top 60±26 44±20 0.024
TOR 111±24 78±29 <0.001
Complications
Haematoma 0 1 1.00
Neurological deterioration 0 0 –
Infection 0 0 –
Diagnostic yield 95 % 95 % 1.00
Length of hospital stay [days]
LOSpre 3 (4) 4 (4) 0.73
LOSpost 2 (4) 2 (3) 1.0
LOSTOTAL 5 (5) 7 (3) 0.16
Tprep—time of the preparation (period from the moment of conscious patient arriving to the operating room to the moment of skin incision),
Top—time of the operation (period from the moment of skin incision to last suture insertion), TOR—total or time (Tprep + Top). LOSpre—preoperative
length of hospital stay, LOSpost—postoperative length of hospital stay, LOSTOTAL—total length of hospital stay
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radiological diagnostic testing in our study was 30 %—which
gives an average of seven patients in each group. There is an
undeniable need to verify these theses basing on a wider group
of participants.
In our trial, the iMRI guidance added approximately 30 min
to conventional surgery time. Pre- and potential intraoperative
image acquisition could usually be done within a few minutes,
but preparation of the operating room and positioning of the
patient in the MRI-compatible head holder are more difficult
than placing the patient’s head in a regular head fixation (e.g., a
Mayfield clamp). However, total time demands could be dif-
ferent if the time spent by the operator on preoperative planning
would be included in the total OR time in the non-iMRI arm.
The independent variables were chosen with a special em-
phasis on making the groups comparable demographically as
well as in terms of the risk factors for bleeding, neurological
Fig. 5 Box graphs showing the
differences between groups in a
mean total length of hospital
stay and b median total OR
time. P values for Mann–
Whitney U (a) and Student’s t
test (b) are presented
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complications or infection [17]. As neither the tumour locali-
zation nor the biopsy trajectory length or its transition through
the brain eloquent areas were recognized as independent
risk factors for the postoperative complications, we decided
not to take them into account as factors influencing the
allocation [17, 20]. We chose minimization as a method of
allocation which could also be considered as a limitation of
our study. Treatment allocation by minimization—in which
the first study participant is allocated to a treatment arm at
random and all subsequent participants are allocated based
on which treatment arm assignment would result in a better
balance between the study groups relative to the variable of
interest—is not the same as randomization [10]. However,
since the desired number of participants required to reveal
the difference of over 5 % between parameters was esti-
mated at the level of 465 patients per each group, we
decided to make both the study and control group compa-
rable in terms of independent variables at each step of the
experiment [6, 31, 34].
Based on available literature stating that non-ferromagnetic
biopsy needles may provide tissue samples of lower histo-
pathological quality, we decided to use a standard side cutting
of 2.2 mm passively navigated ferromagnetic needles in both
groups [16]. This made proper intraoperative visualization of
the needle tip impossible. Although we discovered the pres-
ence of a small air bubble in the site of tissue sampling in all
cases, at the moment, we do not feel authorized to relay on this
promising finding previously described by Czyz et al. [7]. The
number of patients enrolled in the study so far is obviously
insufficient to validate the usefulness of this supplementary
method, but our study is ongoing and we look forward to
further results. This may be treated as an inherent limitation of
our study; since in all previous papers, authors have used
iMRI to verify the accuracy of the biopsy needle placement
[4, 19, 23]. One needs to notice that our intention was to
assume the situation when the usage of iMRI guidance to plan
and perform STx biopsy is favoured because of organizational
conditions rather than obvious indications—biopsy of a cystic
or deep-seated lesion [4, 23]. If intraoperative visualization of
the needle tip would be possible, one could expect an even
higher diagnostic yield than be reported for STx biopsies
carried out without iMRI. The general idea was to widen the
indications for iMRI guidance in STx biopsy beyond the
existing ones.
The possibility to detect a hyperacute intraparenchymal brain
haematoma even with low-field MR imaging was suggested by
numerous authors [2, 4, 5, 11, 35]. On the other hand, Küker
et al. stated that the detection of hyperacute intraparenchymal
blood requires the application of at least three MR sequences
and is, therefore, complicated and time-consuming [14]. None
of the patients from our iMRI-guided group suffered from
postoperative intracerebral bleeding, thus, we did not have a
chance to assess the validity of postoperative T1-weighted iMRI
images in the detection or prediction of early haemorrhagic
complications. Another noteworthy fact to the trial was that
the studied tumours were all large (mean maximum diameters
of 48 and 46 mm for the two groups). Given that low-resolution
(0.15 T) iMRI is able to detect larger lesions better than the small
ones, the qualification of the findings based on tumour size
seems to be justified. Both aspects should be clearly assessed
based on wider clinical material in the nearest future.
Because of the small number of patients involved in our
study, one should consider our results with caution. At this
point of our study we can conclude that the use of iMRI in
stereotactic brain tumour procedures prolongs the time of the
procedure but may be comparable in terms of safety and
efficacy to the standard frameless stereotactic biopsy meth-
od. An obvious advantage of iMRI-guided biopsies is that it
can be considered in cases where no preoperative 3D-MR
scans were acquired, and in such a situation, this technique
may prove time- and cost-effective.
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Comments
Dieter Hellwig, Hanover, Germany
This is a very interesting paper about frameless stereotactic
biopsies using intraoperative low-field MRI guidance. Over years,
the golden standard was the frame-based stereotactic technique to
perform biopsies in histopathological unclarified space occupying
brain lesions. The main drawbacks of the frame-based stereotactic
technique were the lack of mobility and flexibility of the instru-
mentation as well as the so-called “blind” procedure. Therefore,
the endoscope-assisted stereotactic biopsy has been introduced (1).
In the last years, the combination of neuronavigation together
with neuroendoscopy gains in importance, especially for biopsies
of intraventricular tumours (2, 3). The main advantage is that the
procedure is done under direct vision, and the surgeon has much
more freedom in surgical planning and performance. In this study,
Czyz and colleagues showed another suitable technique for “ste-
reotactic” brain tumour biopsies in a safe and effective way. They
used intraoperative low-field MRI as a guidance. The results seem
to be comparable with other stereotactic bioptic techniques under
special consideration of postoperative haematoma and the reliabil-
ity of the histopathological diagnosis. In my opinion, the main
drawback of this technique is that the authors used ferromagnetic
needles, which make the intraoperative visualization of the needle
tip impossible and jeopardize the tremendous advantage with
intraoperative real time control of the biopsy forceps using iMRI.
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Christian Senft, Frankfurt, Germany
Here, Czyz and colleagues report the design of a randomized clinical
trial concerning the use of a mobile intraoperative MRI in stereotactic
biopsies, and they present data from an interim analysis after inclusion
of a pilot group of 42 patients. First of all, the authors are to be
congratulated to perform such a clinical trial. There is a growing need
for solid clinical data to ground decision-making in surgery in general,
particularly in neurosurgery. Especially the use of high-cost technology
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needs to be justified, and only data derived from randomized trials will
convince health care providers to invest in this field. Intraoperative MRI
was introduced into the field of neurosurgery to serve as a means of
resection control in brain tumour surgery and has recently been proven
to be beneficial in a randomized controlled trial [2]. Another area of use
for this technology has been the field of minimal-invasive stereotactic
procedures [1, 3], yet without such high-class scientific proof: once
completed, the study from Czyz and colleagues might be suitable to tell
us neurosurgeons whether there is a benefit from using intraoperative
MRI for these procedures as well. However, a large number of patients
(>900) need to be enrolled according to the study design. I hope the
authors will succeed with patient accrual and will not have to terminate
their study early.
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